Cytodyn Inc (CYDY)

[clambottler]

legitimate reason you think Leronlimab will not be approved for covid19.

If you look at the Phase II trial results, Leronlimab didn't do anything. Do NOT take my word for it - here is the link to the trial and LOOK At the Endpoints.

https://clinicaltrials.gov/ct2/show/NCT04343651?term=Leronlimab&draw=2&rank=4

When the Leronlimab Patients were compared to the Placebo Patients

The Was No Statistically Significant difference; NO DIFFERENCE

No Difference In:

Time to clinical resolution (TTCR) [ Time Frame: Day 14 ]

Change from baseline in the patient's health status on a 7-category ordinal scale [ Time Frame: Days 3, 7, and 14 ]

Incidence of hospitalization [ Time Frame: Day 14 ]

Duration (days) of hospitalization [ Time Frame: Day 14 ]

Incidence of mechanical ventilation supply [ Time Frame: Day 14 ]

Duration (days) of mechanical ventilation supply [ Time Frame: Day 14 ]

Incidence of oxygen use [ Time Frame: Day 14 ]

Duration (days) of oxygen use [ Time Frame: Day 14 ]

Mortality rate [ Time Frame: Day 14 ]

Time to return to normal activity [ Time Frame: Day 14 ]

And either no difference between Leronlimab and the Placebo or they did not run the results OR the CEO has not let anyone know the results
for the following:

Other Outcome Measures:
Change in size of lesion area by chest radiograph or CT [ Time Frame: Day 14 ]
Change from baseline in serum cytokine and chemokine levels [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CD3+, CD4+ and CD8+ T cell count [ Time Frame: Days 3, 7, and 14 ]


Seriously now Time to return to normal activity

The CEO keeps saying Look at News2 Look at News 2

Well who is paying $ 5,000. for a drug when you return to normal activity in the same amount of time by just taking aspirin ?

THERE WAS NO DIFFERENCE BETWEEN PLACEBO AND LERONLIMAB IN THE TIME TO RETURN TO NORMAL ACTIVITY

So what did Leronlimab do ?


xxx.
xx.
x.